Searcharxiv⌕ Search

arXiv subjects

Xinling Wang

Publications and source records attributed to Xinling Wang.

2 recordsLinked to original sources

StreamingDPD: A 1.28-GSa/s Instantaneous-Power-Gated Depthwise TCN Accelerator for Real-Time 320-MHz Digital Predistortion

State feedback between successive samples limits the streaming throughput of recurrent neural networks for digital predistortion (DPD). We present StreamingDPD, an accelerator that processes 320-MHz signals at 1.28 GSa/s. Its 207-parameter instantaneous-power-gated depthwise temporal convolutional network (IPG-DWTCN) uses $|x[n]|^2$ to gate feature channels and causal dilated depthwise convolutions to model power amplifier memory. The network maps to a spatially unrolled fixed-point pipeline with shift-based quadratic activations and layer-wise mixed precision, sustaining one complex sample per cycle per lane. Its algorithmic cost is 554 floating-point operations per complex sample, 30.1% fewer than the recurrent baseline with the best linearization performance. In RF playback measurements on three power amplifiers driven by 40- to 320-MHz Wi-Fi 6/7 and 5G NR waveforms, IPG-DWTCN achieves the lowest mean adjacent-channel power ratio (ACPR) and ranks first or ties for first in mean error vector magnitude (EVM) against five neural baselines of comparable size. Four-lane FPGA hardware-in-the-loop tests on a 320-MHz 4096-QAM Wi-Fi 7 waveform achieve -45.82 dBc ACPR and -42.94 dB EVM at 1.28 GSa/s. At the same sample rate, post-layout evaluation of a single-lane 12-nm FinFET ASIC yields a 0.10 mm$^2$ core, a 52-cycle (40.63 ns) latency, and an estimated typical-corner power of 142.21 mW (111.10 pJ/sample). Relative to the prior 22-nm recurrent DPD ASIC, the design provides 5.1 times the throughput at about one-seventh the energy per sample.

eess.SP↗

DrugAgent: Reliable Multi-Agent Integration of Conflicting Biomedical Evidence for Drug-Target Interaction Assessment

Workflows in drug-target interaction (DTI) assessment require integrating heterogeneous data from predictive models, curated resources, and observations from experimental literature. This evidence can be incomplete or conflicting. DrugAgent is a large language model (LLM)-based multi-agent system focused on DTI evidence integration that integrates outputs from machine learning, knowledge graph, and retrieval-augmented generation (RAG) agents. DrugAgent converts agent outputs into interpretable representations, then summarizes conflict across the evidence. We evaluated DrugAgent on kinase screening data of 900 pairs spanning 178 kinases and 42 inhibitors, and an androgen receptor antagonist screening benchmark. On the kinase dataset, LLM-as-a-Judge evaluation indicated outputs were faithful to input evidence in 98.8% of cases. Biological plausibility of returned summarization was high (scores 3-4 out of 5) across ground-truth classes: 79% of Weak activity labels cases (81% for Moderate/77% Strong); Strong cases received higher scores than Weak/Moderate. Label stability showed 98% agreement across runs. Results on the antagonist benchmark were consistent with the kinase dataset. Retrieved literature provided the greatest benefit when direct drug-target evidence was available, highlighting the importance of evidence availability for RAG-based integration. DrugAgent provides heterogeneous evidence-grounded DTI assessment, complementing standalone DTI prediction. We provide strategies to model agreement, conflict, and uncertainty in biomedical evidence integration. Code: https://github.com/sciluna/DrugAgent.

cs.AI↗